SCHEMBL5871817

SCHEMBL5871817

COc1ccc(Cn2c(=O)cc(O)c3cccnc32)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
THRB P10828 1/20 0.61
PTGDR2 Q9Y5Y4 1/20 0.58
RXFP1 Q9HBX9 2/20 0.53
LMNA P02545 1/20 0.52
TP53 P04637 4/20 0.50
P2RX4 Q99571 1/20 0.48
ENPP2 Q13822 1/20 0.48
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PPARG P37231 2/20 0.46
HKDC1 Q2TB90 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829931 0.85 MEN1 (0.63) MAPTPTGDR2LMNAALDH1A1L3MBTL1
SCHEMBL5871747 0.84 LIPG (0.47) MAPTTHRBPTGDR2LMNATP53
SCHEMBL14224040 0.80 MAPT (0.60) MAPTTHRBPTGDR2RXFP1LMNA
SCHEMBL5872072 0.79 KDM4E (0.60) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL2407901 0.79 PKM (0.52) MAPTTHRBLMNAALDH1A1KDM4E
SCHEMBL5769289 0.77 PTGDR2 (0.60) MAPTTHRBPTGDR2RXFP1LMNA
SCHEMBL1523317 0.77 MAPT (0.59) MAPTTHRBPTGDR2RXFP1LMNA
SCHEMBL5872017 0.76 ALDH1A1 (0.51) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL7651126 0.75 MAPT (0.72) MAPTTHRBPTGDR2RXFP1TP53
SCHEMBL4849772 0.74 PTGDR2 (0.58) MAPTTHRBPTGDR2RXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 MAPT 2184/4885THRB 3266/4885PTGDR2 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.